RC1416

The primary study objective is to evaluate the safety and tolerability of RC1416 injection in healthy subjects after a single subcutaneous injection with increasing doses. The secondary study objective is to evaluate the pharmacokinetic, pharmacodynamic and immunogenic characteristics of RC1416 injection in healthy subjects after a single subcutaneous injection with increasing doses, and to provide a basis for the design of dosing and dosing intervals in subsequent Phase Ib/II studies.